IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025PRNewsWire • 11/19/25
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney CancerPRNewsWire • 11/18/25
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025PRNewsWire • 11/12/25
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial TractionPRNewsWire • 11/10/25
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year SurvivalPRNewsWire • 11/03/25
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation AdvancesPRNewsWire • 10/13/25
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer TreatmentZacks Investment Research • 10/06/25
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive CarePRNewsWire • 10/03/25
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and AbovePRNewsWire • 10/03/25
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies PresentedPRNewsWire • 09/30/25
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies PresentedPRNewsWire • 09/22/25
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ CryoprobesPRNewsWire • 09/18/25
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other IndicationsPRNewsWire • 09/15/25
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation RatePRNewsWire • 09/08/25
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural EfficacyPRNewsWire • 09/04/25
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025PRNewsWire • 08/06/25
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 MillionPRNewsWire • 07/29/25
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with CryoablationPRNewsWire • 07/25/25